Neurosoft Bioelectronics raises $7.5m to progress BCI development

Neurosoft intends to apply the funds towards ongoing clinical trials and US commercialisation efforts for its brain-computer interface (BCI). Neurosoft intends to apply the funds towards ongoing clinical trials and US commercialisation efforts for its brain-computer interface (BCI). Morgan Stanley estimates there to be an early total addressable market (TAM) of $80bn across three million US adults for BCI technology, potentially reaching $320bn with further advancements. Credit: Peshkova / Shutterstock.com Neurosoft Bioelectronics has raised $7.5m to advance the development of its brain-computer interface (BCI). The Swiss company’s oversubscribed seed financing round was led by Skybound Venture Capital, with participation from…

Source: Medical Device Network